Sexual Health · Collection 12

I Love My Partner. So Why Don’t I Want Sex Anymore?

Desire, arousal, menopause, hormones, medications, pain, relationships, and why libido is more complicated than a testosterone level.

The clinical education

Desire is not a testosterone lab value.

Sexual desire is shaped by the brain, body, health, relationships, comfort, stress, and the conditions around intimacy. A hormone result can be one piece of a clinical picture. It cannot tell you whether something is wrong with you.

Desire is not a testosterone lab value.

If pain is part of the story, start there too.

Repeated painful sexual experiences can make it understandable to avoid an activity the body expects to hurt. Read “Why does sex hurt now?” for a focused conversation about pain, evaluation, and treatment that matches the cause.

Sexual interest naturally changes over time. Some women notice spontaneous desire: an interest that seems to appear on its own. Others experience responsive desire: interest that may develop after wanted affection, erotic cues, or pleasurable touch begins. Many experience both, or experience desire differently at different points in life. Responsive desire is not a requirement to continue with sexual activity; consent and genuine interest still matter at every step.

There is no single frequency of sex, amount of spontaneous desire, or serum testosterone level that defines a healthy libido for every woman. A woman who is content with her level of desire does not need treatment just because it differs from a partner’s or from a cultural expectation.

Clinicians use more than one diagnostic framework. The DSM-5-TR groups aspects of interest and arousal under female sexual interest/arousal disorder. ICD-11 calls the desire-focused diagnosis hypoactive sexual desire dysfunction; many U.S. clinical discussions and FDA labels still use hypoactive sexual desire disorder (HSDD). These terms are not labels for every quiet season. Evaluation centers on a persistent or recurrent change that the woman herself experiences as unwanted and distressing, along with its pattern, context, and possible contributors. Screening questionnaires can help organize a conversation; none replaces clinical assessment.

A low blood testosterone result does not diagnose HSDD. Testosterone levels do not reliably separate women with distressing low desire from women without it. Testing may be useful when a clinician is considering testosterone treatment, including to establish a baseline and monitor safety, but there is no laboratory threshold that diagnoses low desire.

The partner question

Your partner’s desired frequency is not the laboratory reference range for your libido. A difference in desire does not automatically mean either person is dysfunctional. The goal is not to make one person match another person’s preferred frequency. Your own wishes, comfort, and autonomy stay at the center.

Why can desire change?

There may be one contributor or several. Sexual pain can teach the body to expect discomfort. Genitourinary syndrome of menopause (GSM) may cause dryness or tissue discomfort. Hot flashes, night sweats, disrupted sleep, fatigue, depression, anxiety, chronic illness, cancer treatment, medications, caregiving, relationship changes, and limited privacy may all affect interest. Arousal, orgasm, body image, and a partner’s health or sexual function may also change the experience. Sometimes a woman cannot identify one cause, and that does not make her concern less real.

Menopause may be part of the story, but it does not automatically “kill” desire. Vaginal estrogen can treat GSM when appropriate; it is not a libido medication. Treating painful dryness may remove one barrier to wanted, comfortable sexual activity without directly creating desire.

Myths that deserve a better answer

“My testosterone must be low.” A low number does not diagnose HSDD, and a normal number does not rule out distressing sexual symptoms.
“There is one normal testosterone level for desire.” There is no such diagnostic threshold. Desire is not read from a laboratory reference range.
“If I love my partner, I should want sex.” Love and sexual desire are related for some people, but they are not the same thing.
“If I don’t initiate, I have low libido.” Initiation is only one behavior. Some women rarely initiate and still enjoy wanted sexual activity.
“Menopause kills your sex drive.” Menopause can affect sleep, comfort, arousal, and desire, but women’s experiences vary and contributing symptoms may be treatable.
“Testosterone fixes every sexual problem.” It may help appropriately selected postmenopausal women with HSDD. It does not treat every cause of pain, fatigue, medication effects, relationship strain, or altered arousal.
“If sex is physically possible, pain shouldn’t affect desire.” Pain, fear of pain, or bracing for pain can change what the body wants to approach. See our Painful Sex collection.
“Everyone should want sex a certain number of times per week.” There is no universal required frequency.
“If my partner wants sex more often, something must be wrong with me.” Desire discrepancy is not, by itself, a diagnosis in either partner.

A composite experience

“I love him. I just don’t want sex the way I used to.”

This composite vignette reflects experiences women commonly describe. It is not the story of one identifiable patient.

She does love her partner. She likes being close. She misses the version of herself who used to feel curious, playful, or ready. But lately, sex feels like another item waiting for her after work, caregiving, and trying to get a full night of sleep.

At first, she thought menopause had taken her desire. Then she noticed that penetration had started to sting. She began to tense before sex, because she could predict the part that might hurt. She also wondered whether an antidepressant was affecting arousal and orgasm. Her partner felt rejected; she felt guilty and watched for signs that she was supposed to initiate.

“I love my partner. So why don’t I want sex anymore?” is a question, not a confession.

When she finally brought it up, no one asked her to prove love by having sex. The clinician asked what had changed, whether the change bothered her, what kinds of intimacy she wanted, what felt comfortable, and whether desire ever arrived after wanted closeness began. They discussed pain, menopause symptoms, sleep, mood, medication timing, relationship context, and what she hoped might be different.

She learned that her body was not a single switch that had broken. Treating GSM-related discomfort and making a clinician-guided medication plan gave her more room to decide what she wanted. Desire did not return on command, and her worth was never dependent on it. She and her partner began to talk about intimacy without treating frequency as a report card.

Where women see themselves

You can love your partner and not want sex right now. You can want closeness without penetration. You can have low desire that is not a problem for you. And if a change is troubling you, you deserve a conversation that starts with your experience rather than blame.

Dr. Rhaney’s perspective

Before I treat desire, I want to understand what changed.

I do not begin with a hormone result or a target number of sexual encounters. I begin with the woman: what she is noticing, whether she wants help, and what she wants her sexual life to feel like.

I ask when the change began and whether it was gradual or sudden. Is it present in every situation, or does it depend on a partner, kind of touch, time, privacy, or the possibility of pain? Does desire ever show up after wanted touch starts? Has arousal or orgasm changed too? Is sex pleasurable, neutral, pressured, painful, or unsafe? Does the woman feel personal distress, or is the concern mainly someone else’s expectation? These questions help distinguish a change that merits support from normal variation that a woman does not want to change.

When pain is part of the story, I do not diagnose primary low desire before considering what the body may have learned to anticipate. Repeated painful experiences can make avoidance understandable. I ask where it hurts, when it happens, and whether there are symptoms of dryness, burning, bleeding, skin changes, pelvic-floor guarding, or deeper pelvic pain. A targeted examination may be appropriate when physical symptoms call for one; a woman should not have to accept an unwanted examination to be believed. Read more in “Why does sex hurt now?”

I also ask about sleep, night sweats, hot flashes, fatigue, mood, chronic illness, cancer treatment, surgery, and medicines. Some antidepressants, blood pressure medicines, and other treatments can affect desire, arousal, or orgasm for some people. A medication review is a conversation with the prescriber, not an instruction to stop a medicine abruptly.

Testing is guided by the history and examination. There is not one hormone panel that explains low desire. If symptoms suggest a thyroid, prolactin, or other medical contributor, a clinician may consider focused testing. A testosterone level is not a diagnostic test for HSDD. If testosterone is being considered, baseline measurement and follow-up have a safety-monitoring role.

For a postmenopausal woman who has a distressing, persistent desire change that fits HSDD after comprehensive assessment, physiologic-dose transdermal testosterone may be considered through shared decision-making. In the United States, testosterone is not FDA-approved specifically for female HSDD as of September 2026. A recent FDA workshop examined evidence gaps and possible future research; it did not itself create an approved female product. The strongest evidence is for a moderate average benefit in appropriately selected postmenopausal women, not a guaranteed response or a treatment for all sexual concerns.

Baseline total testosterone and SHBG are used to check for an already high level and support safe dosing, not to prove the diagnosis. If treatment is chosen, total testosterone is typically rechecked about three to six weeks after starting or changing the dose, then every four to six months once stable; the goal is to stay within the physiologic range for premenopausal women. Compounded testosterone is generally not preferred when an appropriately adapted regulated product is available. Pellets, injections, or any approach that can produce excessive levels should not be casually normalized. Acne and unwanted hair growth may occur; voice changes or clitoral enlargement can be difficult to reverse. Evidence about safety beyond about 24 months is limited, and trials do not answer every question about cardiovascular or breast-cancer risk. For a history of hormone-sensitive cancer, safety data are limited and discussion should be individualized, with the oncology team involved when appropriate. Our Cancer Survivorship collection explores that care in more depth.

My goal is not to make a woman want sex for somebody else. It is to understand what changed and help her make an informed choice about her own care.

Felicia L. Rhaney, MD, FACOG, MSCP
Double board-certified OB-GYN and urogynecologist

The decision guide

Before we treat desire, we need to understand what is getting in its way.

There is no generic libido checklist. A useful plan follows the contributors that fit your experience and your goals. More than one may need attention, and you may decide you do not want treatment.

Treat pain first when pain is part of the story

Repeated painful sexual experiences can suppress desire or lead the body to anticipate discomfort. That does not automatically mean pain is the only cause, but it deserves attention before low desire is labeled primary. Evaluation and treatment depend on where it hurts and what is contributing. Start with our Painful Sex collection.

Address GSM when it is present

When menopause-related tissue changes cause dryness, burning, or discomfort, GSM care may help. Lubricants can reduce friction during sexual activity; vaginal moisturizers are used regularly for dryness; and local vaginal estrogen or other approved therapies may be appropriate for some women after discussion of their health history. Vaginal estrogen is not a libido medication. Relieving tissue discomfort may remove a barrier to comfortable sex without directly creating desire. For cancer history and treatment-specific questions, see our Cancer Survivorship collection. Menopause symptoms and hormone testing are also discussed in our menopause collection.

Consider sleep, menopause symptoms, and fatigue

Night sweats, hot flashes, insomnia, fatigue, and other health burdens can leave little energy for sexual interest. Treat the symptoms that are actually affecting you. Menopause treatment may improve sleep or comfort for some women, but no treatment automatically restores libido. See our midlife sleep collection for a fuller discussion of sleep disruption.

Review medicines with the prescribing clinician

If desire, arousal, or orgasm changed after a medication was started or its dose changed, bring that timeline to the prescriber. They can review whether the medicine may contribute and whether a safe adjustment or alternative makes sense. Do not stop, skip, or change a prescribed medicine on your own.

Make room for relationship and life context

Communication, relationship satisfaction, caregiving, privacy, stress, routine, mismatched desire, a partner’s health or sexual function, and other circumstances may matter. None should be assumed to be the cause, and a woman does not simply need romance or a date night to fix a health concern. If it fits her goals, sexual counseling or therapy can be one part of integrated care.

Discuss testosterone only when the evidence and assessment fit

For an appropriately selected postmenopausal woman with HSDD after a comprehensive assessment, testosterone may be considered. Treatment is guided by symptoms and clinical assessment, not by a “low” result. Baseline and follow-up testosterone testing help with safe prescribing; they do not diagnose HSDD. When used, dosing should remain in the physiologic female range, with monitoring for levels, benefit, and side effects. Compounded products are generally not preferred when a regulated formulation can be carefully adapted. Pellets and injections that may produce excessive levels are not recommended. Long-term safety beyond the available study period remains uncertain. For the detailed conversation about what testosterone can and cannot do, see “She was told testosterone would fix everything.”

Know what FDA-approved HSDD medicines are for

These medicines are options for selected patients, not universal “libido drugs,” and medication is not necessary for every woman with low desire. Both FDA-approved labels use acquired, generalized HSDD: a distressing change from a prior pattern that occurs across situations and partners and is not better explained by a medical or psychiatric condition, relationship problem, or medication or drug effect. Although flibanserin’s label includes “interpersonal difficulty,” a clinician should not treat a partner’s preferred frequency alone as the woman’s diagnosis or treatment goal.

Flibanserin (Addyi) is indicated for women younger than 65, including premenopausal and postmenopausal women, with acquired, generalized HSDD. It is taken by mouth every night at bedtime, not as needed; it should be stopped after eight weeks if symptoms have not improved. Important safety issues include sleepiness, dizziness, low blood pressure or fainting, and interactions. The label advises waiting at least two hours after one or two standard drinks before the bedtime dose, or skipping it that evening after three or more drinks. It is contraindicated with moderate or strong CYP3A4 inhibitors and in people with hepatic impairment. A clinician or pharmacist should review the current label and full medication list before prescribing.

Bremelanotide (Vyleesi) is indicated only for premenopausal women with acquired, generalized HSDD. It is a self-injection used as needed at least 45 minutes before anticipated sexual activity. Do not use more than one dose in 24 hours or more than eight doses in a month; stop after eight weeks if there is no improvement. Nausea was reported by about 40% of trial participants, and focal skin pigmentation can occur and may not fully resolve. It can temporarily raise blood pressure and lower heart rate; it is contraindicated with uncontrolled hypertension or known cardiovascular disease and is not recommended for people at high cardiovascular risk. It can slow stomach emptying and affect absorption of some oral medicines; avoid combining it with oral naltrexone used for alcohol or opioid use disorder. It is not indicated for postmenopausal women or to enhance sexual performance. If pregnancy is possible, discuss contraception and stop if pregnancy is suspected. The current FDA label should guide individual decisions.

Consider sexual counseling or therapy without blame

Sex therapy, cognitive behavioral approaches, or other counseling may help when psychological, relational, behavioral, trauma-related, or contextual factors contribute. These approaches can be evidence-informed parts of care alongside medical treatment. They do not mean the problem is “in your head,” and a woman should not be sent to therapy instead of having pain, medication effects, or other health concerns assessed.

Be discerning about supplements

Libido gummies, “hormone balancing” products, testosterone boosters, adrenal or cortisol supplements, and proprietary sexual-enhancement blends are heavily marketed. Claims may go beyond the evidence, while ingredient quality, dose, interactions, and safety can vary. A supplement label does not guarantee effectiveness or safety. Bring products you use to a clinician or pharmacist for an interaction review; this collection does not endorse unproven products.

When low desire deserves a closer look

Consider an appointment if you notice a significant unexplained change from your baseline; the change causes you personal distress; sex is painful; arousal or orgasm has changed; symptoms began after a medication change; mood symptoms or menopause symptoms are affecting quality of life; cancer treatment or a major illness changed sexual function; an endocrine or other medical contributor is suspected; or you simply want help understanding what changed. You do not need to prove that the concern is severe enough before asking.

Questions you can bring to a visit

What changed, when did I first notice it, and what parts of my sexual experience changed?
Could pain, GSM, sleep, mood, a medication, or another health issue be contributing?
Does my experience fit a diagnosis that needs treatment, or is this a level of desire I am comfortable with?
If testosterone is being considered, what diagnosis are we treating, how will the dose stay within the physiologic range, and how will we monitor it?
Would an FDA-approved HSDD medicine fit my age, health history, symptoms, and goals? What are its label limits and risks?
What are the alternatives, including addressing contributors or choosing no treatment for now?

Your choices count. The aim is not a particular sexual frequency or a partner’s preferred level of desire. It is care that respects your health, comfort, autonomy, and goals. Do not start, stop, or change medicines or supplements without an individualized review with a qualified clinician.

Clinical review

Educational content reviewed September 2026 by Felicia L. Rhaney, MD, FACOG, MSCP. This material supports, but does not replace, individualized evaluation and care.

Selected guidance

Continue exploring

One topic. A fuller conversation.

Return to The Knowledge Hub

Your desire belongs to you. Your questions deserve care.